![]() ![]() During her tenure, she was responsible for progressing several projects to clinical trials and collaborated closely with the company’s Early Development Groups to establish translational approaches, including biomarker discovery and proof of mechanism studies.ĭr. ![]() Fuentes has previously held leadership positions at Roche (Palo Alto) and Hoffmann-La Roche (Nutley, NJ), including as Research Director and Head of the Respiratory Drug Discovery Group. In this position her focus was to advance into the clinic small molecules and antibody therapeutics for the treatment of fibrotic diseases, including interstitial pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH).ĭr. Prior to Blade, she was Group Director, Fibrosis Discovery Biology at Bristol-Myers Squibb. Maria developed pre-clinical and biomarker strategy and provided key data for advancement of three cysteine protease inhibitors in fibrotic and neurodegenerative diseases. Most recently, Maria led Blade Therapeutics biology and translational activities to advance programs to clinical development, as Blade’s Executive Vice President of Research. Combined with the significant progress Mantra Bio has made over the past 4 years in refining and validating its Targeted Exosome delivery platform (REVEAL), Maria’s deep experience in translational development will accelerate Mantra’s unique platform towards clinical success. Maria has led preclinical teams to advance programs across multiple therapeutic areas, including respiratory, autoimmune, fibrosis and others. Fuentes is a seasoned drug discovery executive with a track record of advancing multiple assets into the clinic. Outside of work, Andrew coaches fitness and ballet, and also enjoys cooking and hiking.ĭr. Andrew also holds Bachelor’s degrees in both Mathematics and Ballet from Indiana University. in Bioinformatics from George Mason University and completed postdoctoral work at the University of North Carolina Charlotte where he managed the computational lab for micro-array biophysics research, while serving as DataFATE lead and project manager. As adjunct faculty at UNCC Andrew explored Covid-19 mRNA molecular structure and propagation through a combination of machine learning and bioinformatics tools, for linkage in potential exogenistic molecular catalysis for genetic predisposed diseases.Īndrew holds a Ph.D. ![]() In a previous position as Director of Bioinformatics at Accelerated Technology Laboratories Andrew developed high through-put GPGPU accelerated algorithms for parsing bioinformatics data to provide faster sequence comparison across multiple genomic targets. Andrew Carr is a Data Scientist with expertise in algorithms, machine learning, and database design, and is responsible for advancing Mantra Bio’s targeted exosome technologies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |